

**ANNOUNCEMENT NO. 217**

19 January 2022

**Major shareholder announcement**

Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that BlackRock, Inc. has informed ChemoMetec A/S that BlackRock, Inc. holds 872,179 shares in ChemoMetec A/S corresponding to 5.01% of the share capital, and that the company's shareholding thus exceeds the 5 per cent limit in section 38 of the Capital Markets Act.

**For further information, please contact**

Steen Søndergaard, CEO, ChemoMetec A/S  
Tel: (+45) 4813 1020

**About ChemoMetec A/S**

*ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec's customers include some of the world's leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.*

*ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go to [www.chemometec.com](http://www.chemometec.com).*